Stay updated on Dupilumab in Bullous Pemphigoid Adults Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page.

Latest updates to the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.5.2.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.5.0 added. Revision: v3.4.3 removed.SummaryDifference0.0%

- Check41 days agoChange DetectedResults posted on 2026-03-06 introduce a comprehensive Results section with primary and secondary efficacy outcomes (OCS exposure, BPDAI scores, pruritus NRS, ABQOL, BP involvement, and autoantibody titers) plus safety data through Week 64. Several previously reported metrics (e.g., sustained remission proportions and some BPDAI-related endpoints) were removed.SummaryDifference6%

- Check70 days agoChange DetectedA new site revision entry (Revision: v3.4.2) was added, and the notice about a lapse in government funding was removed; these are minor administrative updates that do not alter the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check77 days agoChange DetectedAdded a banner informing users about the lapse in government funding and NIH operating status with links to cc.nih.gov and opm.gov. Updated the site version from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check84 days agoChange DetectedShow glossary feature added and two QC-related date fields introduced (Last Update Submitted that Met QC Criteria, Last Update Posted). The revision was updated to v3.4.0 and No FEAR Act data references were adjusted.SummaryDifference0.2%

Stay in the know with updates to Dupilumab in Bullous Pemphigoid Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page.